DBV Technologies S.A.
DBV
Rank in Stocks
#10463
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on... DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
Share Price
$2.20
Last synced: 2026-11-09
Market Cap
$691.14M
Change (1 day)
9.93%
Change (1 year)
-21.87%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade DBV Technologies S.A. (DBV)
Category
Healthcare
Operating Margin for DBV Technologies S.A. (DBV)
Operating Margin as of November 2026 TTM: -3,687.06%
According to DBV Technologies S.A.'s latest financial reports, its current operating margin (TTM) is -3,687.06%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for DBV Technologies S.A. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -3,687.06% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -2,808.70% | 477.96% |
| 2023 | -485.97% | -75.86% |
| 2022 | -2,013.15% | 16.53% |
| 2021 | -1,727.65% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -22,547.53% | 92.89% |
| 2014 | -11,689.15% | 6.51% |
| 2013 | -10,974.91% | 41.70% |
| 2012 | -7,745.10% | 34.46% |
| 2011 | -5,760.35% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about DBV Technologies S.A.'s operating margin
What is DBV Technologies S.A.'s operating margin?
DBV Technologies S.A.'s operating margin is -3,687.06%, as of Nov 2026.
What was DBV Technologies S.A.'s operating margin in 2025?
In 2025, DBV Technologies S.A.'s operating margin was 0.00%, compared with -2,808.70% in 2024.
How has DBV Technologies S.A.'s operating margin changed since 2020?
From 2020 to 2025, DBV Technologies S.A.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-2,808.70%).
How does DBV Technologies S.A.'s operating margin compare with similar companies?
DBV Technologies S.A.'s operating margin (-3,687.06%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.